Daiichi Sankyo Company, Limited (DSKYF)

Market Cap	54.84B
Revenue (ttm)	12.27B
Net Income (ttm)	1.75B
Shares Out	n/a
EPS (ttm)	0.91
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Open	27.89
Previous Close	31.55
Day's Range	27.89 - 27.89
52-Week Range	25.95 - 44.64
Beta	0.28
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 31, 2024

About Daiichi Sankyo Company

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation; Vanflyta, a FLT3 inhi...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1899
• Employees: 18,726
• Stock Exchange: OTCMKTS
• Ticker Symbol: DSKYF

Financial Performance

In 2023, Daiichi Sankyo Company's revenue was 1.60 trillion, an increase of 25.28% compared to the previous year's 1.28 trillion. Earnings were 200.73 billion, an increase of 83.84%.

Financial numbers in JPY